dc.creator | Murcia Casas, Belén | es |
dc.creator | Carrillo Linares, Juan Luis | es |
dc.creator | Baquero Aranda, Isabel | es |
dc.creator | Rioja Villodres, José | es |
dc.creator | Merino Bohórquez, Vicente | es |
dc.creator | González Jiménez, Andrés | es |
dc.creator | Rico Corral, Miguel Ángel | es |
dc.creator | Valdivielso, Pedro | es |
dc.date.accessioned | 2024-04-05T07:32:00Z | |
dc.date.available | 2024-04-05T07:32:00Z | |
dc.date.issued | 2023-03-03 | |
dc.identifier.citation | Murcia Casas, B., Carrillo Linares, J.L., Baquero Aranda, I., Rioja Villodres, J., Merino Bohórquez, V., González Jiménez, A.,...,Valdivielso, P. (2023). Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial. International Journal of Molecular Sciences, 24 (5), 4899. https://doi.org/10.3390/ijms24054899. | |
dc.identifier.issn | 1422-0067 | es |
dc.identifier.issn | 1661-6596 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156676 | |
dc.description.abstract | Pseudoxanthoma elasticum (PXE) is characterized by low levels of inorganic pyrophosphate
(PPi) and a high activity of tissue-nonspecific alkaline phosphatase (TNAP). Lansoprazole is a partial
inhibitor of TNAP. The aim was to investigate whether lansoprazole increases plasma PPi levels in
subjects with PXE.We conducted a 2 2 randomized, double-blind, placebo-controlled crossover
trial in patients with PXE. Patients were allocated 30 mg/day of lansoprazole or a placebo in two
sequences of 8 weeks. The primary outcome was the differences in plasma PPi levels between
the placebo and lansoprazole phases. 29 patients were included in the study. There were eight
drop-outs due to the pandemic lockdown after the first visit and one due to gastric intolerance, so
twenty patients completed the trial. A generalized linear mixed model was used to evaluate the
effect of lansoprazole. Overall, lansoprazole increased plasma PPi levels from 0.34 0.10 M to
0.41 0.16 M (p = 0.0302), with no statistically significant changes in TNAP activity. There were no
important adverse events. 30 mg/day of lansoprazole was able to significantly increase plasma PPi
in patients with PXE; despite this, the study should be replicated with a large number of participants
in a multicenter trial, with a clinical end point as the primary outcome. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | International Journal of Molecular Sciences, 24 (5), 4899. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | pseudoxanthoma elasticum | es |
dc.subject | inorganic pyrophosphate | es |
dc.subject | lansoprazole | es |
dc.subject | tissue-nonspecific alkaline phosphatase | es |
dc.title | Lansoprazole increases inorganic pyrophosphate in patients with pseudoxanthoma elasticum: a double-blind, randomized, placebo-controlled crossover trial | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | |
dc.relation.publisherversion | https://doi.org/10.3390/ijms24054899 | es |
dc.identifier.doi | 10.3390/ijms24054899 | es |
dc.journaltitle | International Journal of Molecular Sciences | es |
dc.publication.volumen | 24 | es |
dc.publication.issue | 5 | es |
dc.publication.initialPage | 4899 | es |
dc.contributor.funder | Asociación Española de Afectados por PXE | es |